News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Everolimus improves the efficacy of dasatinib in PDGFRa-driven glioma


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Look at your pathology report to see if you have the PDGFRα mutation...  if so it might be worth considering this combination!  It is early work but they did the research the right way - they came up with a theory, tested it in the lab and in animals, then tried it on a small group of people and it did pretty well.   The Musella Foundation helped support this project through our collaboration with the DIPG Collaborative.


Posted on: 07/03/2020

Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740